Search Results for: NCOA1

Novel Interactant Symbol Name
Associated Pathways
Binding Drugs
Associated Diseases
Novel CHMP2A charged multivesicular body protein 2A
  • Budding and maturation of HIV virion
  • Macroautophagy
  • Lysosome Vesicle Biogenesis
  • Pyroptosis
  • Endosomal Sorting Complex Required For Transport (ESCRT)
  • HCMV Late Events
  • Late endosomal microautophagy
  • Sealing of the nuclear envelope (NE) by ESCRT-III
  • Translation of Replicase and Assembly of the Replication Transcription Complex
  • Translation of Replicase and Assembly of the Replication Transcription Complex
Novel CPS1 carbamoyl-phosphate synthase 1
  • Urea cycle
  • Carglumic acid
  • Carbamoyl phosphate synthetase I deficiency
Novel CYB561 cytochrome b561
Novel HADHA hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit alpha
  • Acyl chain remodeling of CL
  • Beta oxidation of myristoyl-CoA to lauroyl-CoA
  • mitochondrial fatty acid beta-oxidation of unsaturated fatty acids
  • Beta oxidation of palmitoyl-CoA to myristoyl-CoA
  • Beta oxidation of lauroyl-CoA to decanoyl-CoA-CoA
  • Beta oxidation of decanoyl-CoA to octanoyl-CoA-CoA
  • Beta oxidation of octanoyl-CoA to hexanoyl-CoA
  • Beta oxidation of hexanoyl-CoA to butanoyl-CoA
  • NADH
  • Disorders of fatty-acid oxidation, including: Medium-chain (MC) acyl-CoA dehydrogenase (AD) deficiency (MCADD); Short-chain AD deficiency (SCADD) ; Short-branched-chain AD deficiency (SBCADD) ; Very long-chain AD deficiency (VLCADD) ; Long-chain 3-hydroxyacyl CoA dehydrogenase deficiency (LCHADD) ; Trifunctional protein deficiency (TFP); Carnitine palmitoyltransferase deficiency (CPT); Carnitine-acylcarnitine translocase deficiency (CACT); Systemic primary carnitine deficiency (CDSP)
  • Mitochondrial respiratory chain deficiencies (MRCD), including: Mitochondrial complex I deficiency (MT-C1D); Complex II deficiency (MT-C2D); Complex III deficiency (MT-C3D); Complex IV deficiency (MT-C4D); Complex V deficiency (MT-ATPSD); Leigh syndrome (LS); Kearns-Sayre Syndrome (KSS); LCHD deficiency (LCHD); Leber Hereditary Optic Neuropathy (LHON); Myoclonic Epilepsy and Ragged-Red Fiber Disease (MERRF); NARP; MELAS; ACAD9 deficiency; HADH deficiency; HIBCH deficiency; GRACILE syndrome
Novel PPM1B protein phosphatase, Mg2+/Mn2+ dependent 1B
  • ISG15 antiviral mechanism
  • ALK mutants bind TKIs
  • Signaling by ALK fusions and activated point mutants
Novel PPP1CB protein phosphatase 1 catalytic subunit beta
  • Triglyceride catabolism
  • Downregulation of TGF-beta receptor signaling
  • Regulation of PLK1 Activity at G2/M Transition
  • RHO GTPases activate PKNs
  • RHO GTPases activate PKNs
  • RHO GTPases activate CIT
  • RHO GTPases Activate ROCKs
  • RHO GTPases activate PAKs
  • RHO GTPases activate PAKs
  • RAF activation
  • SHOC2 M1731 mutant abolishes MRAS complex function
  • Gain-of-function MRAS complexes activate RAF signaling
  • Maturation of hRSV A proteins
  • Phosphorylation and nuclear translocation of the CRY:PER:kinase complex
Novel SLC28A2 solute carrier family 28 member 2
  • Transport of nucleosides and free purine and pyrimidine bases across the plasma membrane
  • Azathioprine ADME
  • Ribavirin ADME
Novel SRD5A2 steroid 5 alpha-reductase 2
  • Androgen biosynthesis
  • Spironolactone
  • Azelaic acid
  • Dutasteride
  • Finasteride
  • 46,XY disorders of sex development (Disorders in androgen synthesis or action), including: Congenital adrenal hyperplasias; Leydig cell hypoplasia; Androgen insensitivity syndrome (AIS)
Novel ZNF512 zinc finger protein 512
AHR aryl hydrocarbon receptor
  • PPARA activates gene expression
  • Phase I - Functionalization of compounds
  • Endogenous sterols
  • Xenobiotics
  • Aryl hydrocarbon receptor signalling
  • Omeprazole
  • Mexiletine
  • Nimodipine
  • Flutamide
  • Atorvastatin
  • Leflunomide
  • Ginseng
  • Indirubin-3'-monoxime
  • Resveratrol
  • Quercetin
  • Tapinarof
  • beta-Naphthoflavone
  • Emodin
  • 1-[(4S)-4-amino-5-(1,3-benzothiazol-2-yl)-5-oxopentyl]guanidine
  • Diosmin
  • Kynurenic Acid
  • Epigallocatechin gallate
  • Cantharidin
  • Indirubin
  • Carbendazim
  • Indigo
ANKRD11 ankyrin repeat domain containing 11
AR androgen receptor
  • HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand
  • Nuclear Receptor transcription pathway
  • SUMOylation of intracellular receptors
  • Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3
  • Ub-specific processing proteases
  • RUNX2 regulates osteoblast differentiation
  • RUNX2 regulates osteoblast differentiation
  • Diethylstilbestrol
  • Levonorgestrel
  • Progesterone
  • Spironolactone
  • Flutamide
  • Oxandrolone
  • Fluphenazine
  • Testosterone
  • Mitotane
  • Estrone
  • Nilutamide
  • Tamoxifen
  • Norethisterone
  • Drostanolone
  • Norgestimate
  • Nandrolone phenpropionate
  • Ketoconazole
  • Acetophenazine
  • Bicalutamide
  • Fluoxymesterone
  • Drospirenone
  • Danazol
  • Testosterone propionate
  • Oxybenzone
  • 1-Testosterone
  • Boldenone
  • Calusterone
  • Periciazine
  • Prasterone
  • Flufenamic acid
  • Stanolone
  • (R)-Bicalutamide
  • Metribolone
  • (3AALPHA,4ALPHA,7ALPHA,7AALPHA)- 3A,4,7,7A-TETRAHYDRO-2-(4-NITRO-1-NAPHTHALENYL)-4,7-ETHANO-1H-ISOINDOLE-1,3(2H)-DIONE
  • Cyproterone acetate
  • LGD2941
  • Dimethylcurcumin
  • Oxymetholone
  • Methyltestosterone
  • Norelgestromin
  • Stanozolol
  • Tetrahydrogestrinone
  • (2S)-N-(4-cyano-3-iodophenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide
  • BMS-564929
  • S-23
  • 4-{[(1R,2S)-1,2-dihydroxy-2-methyl-3-(4-nitrophenoxy)propyl]amino}-2-(trifluoromethyl)benzonitrile
  • (2S)-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]-3-(pentafluorophenoxy)propanamide
  • Andarine
  • (R)-3-BROMO-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE
  • (5S,8R,9S,10S,13R,14S,17S)-13-{2-[(3,5-DIFLUOROBENZYL)OXY]ETHYL}-17-HYDROXY-10-METHYLHEXADECAHYDRO-3H-CYCLOPENTA[A]PHENANTHREN-3-ONE
  • S-3-(4-FLUOROPHENOXY)-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE
  • 1-TERT-BUTYL-3-(2,5-DIMETHYLBENZYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE
  • 4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-1-NAPHTHONITRILE
  • 2-chloro-4-{[(1R,3Z,7S,7aS)-7-hydroxy-1-(trifluoromethyl)tetrahydro-1H-pyrrolo[1,2-c][1,3]oxazol-3-ylidene]amino}-3-methylbenzonitrile
  • LGD-2226
  • 3-[(4-AMINO-1-TERT-BUTYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL)METHYL]PHENOL
  • Triclosan
  • Nandrolone decanoate
  • Ulipristal
  • Enzalutamide
  • Eugenol
  • Dienogest
  • Norethynodrel
  • Norgestrel
  • Homosalate
  • Enzacamene
  • Luprostiol
  • Mibolerone
  • Phenothiazine
  • Gestrinone
  • Apalutamide
  • Clascoterone
  • Darolutamide
  • Esculin
  • Ligandrol
  • Testosterone cypionate
  • Testosterone enanthate
  • Testosterone undecanoate
  • Stanolone acetate
  • Segesterone acetate
  • Boldenone undecylenate
  • Echinacoside
  • Ketodarolutamide
  • Spinal and bulbar muscular atrophy (SBMA); Kennedy's disease
  • 46,XY disorders of sex development (Other), including: Persistent Mullerian duct syndrome; Hypospadias; Cryptorchidism
  • Prostate cancer
  • 46,XY disorders of sex development (Disorders in androgen synthesis or action), including: Congenital adrenal hyperplasias; Leydig cell hypoplasia; Androgen insensitivity syndrome (AIS)
ARID1A AT-rich interaction domain 1A
  • RMTs methylate histone arginines
  • RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known
  • Positive Regulation of CDH1 Gene Transcription
  • Regulation of MITF-M-dependent genes involved in pigmentation
  • Regulation of MITF-M-dependent genes involved in pigmentation
  • Regulation of endogenous retroelements by Piwi-interacting RNAs (piRNAs)
  • Formation of the canonical BAF (cBAF) complex
  • Formation of the embryonic stem cell BAF (esBAF) complex
  • Formation of neuronal progenitor and neuronal BAF (npBAF and nBAF)
  • Formation of neuronal progenitor and neuronal BAF (npBAF and nBAF)
ARNT aryl hydrocarbon receptor nuclear translocator
  • Regulation of gene expression by Hypoxia-inducible Factor
  • PPARA activates gene expression
  • Phase I - Functionalization of compounds
  • Endogenous sterols
  • Xenobiotics
  • Aryl hydrocarbon receptor signalling
  • NPAS4 regulates expression of target genes
  • NPAS4 regulates expression of target genes
BCL3 BCL3 transcription coactivator
CARM1 coactivator associated arginine methyltransferase 1
  • BMAL1:CLOCK,NPAS2 activates circadian expression
  • PPARA activates gene expression
  • PPARA activates gene expression
  • Transcriptional activation of mitochondrial biogenesis
  • Activation of gene expression by SREBF (SREBP)
  • RMTs methylate histone arginines
  • Transcriptional regulation of white adipocyte differentiation
  • Regulation of lipid metabolism by PPARalpha
  • TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest
  • Estrogen-dependent gene expression
  • Cytoprotection by HMOX1
  • Heme signaling
  • Expression of BMAL (ARNTL), CLOCK, and NPAS2
  • RORA,B,C and NR1D1 (REV-ERBA) regulate gene expression
CCND1 cyclin D1
  • SCF(Skp2)-mediated degradation of p27/p21
  • Pre-NOTCH Transcription and Translation
  • RMTs methylate histone arginines
  • Interleukin-4 and Interleukin-13 signaling
  • Cyclin D associated events in G1
  • Ubiquitin-dependent degradation of Cyclin D
  • Ubiquitin-dependent degradation of Cyclin D
  • PTK6 Regulates Cell Cycle
  • Transcriptional Regulation by VENTX
  • Transcriptional regulation by RUNX2
  • Regulation of RUNX1 Expression and Activity
  • RUNX3 regulates WNT signaling
  • RUNX3 regulates p14-ARF
  • Estrogen-dependent gene expression
  • Estrogen-dependent nuclear events downstream of ESR-membrane signaling
  • Defective binding of RB1 mutants to E2F1,(E2F2, E2F3)
  • Drug-mediated inhibition of CDK4/CDK6 activity
  • Regulation of MITF-M-dependent genes involved in cell cycle and proliferation
  • SPOP-mediated proteasomal degradation of PD-L1(CD274)
  • Acetylsalicylic acid
  • Arsenic trioxide
  • Encorafenib
  • Bryostatin 1
  • Breast cancer
  • Hairy-cell leukemia
  • Oral cancer
  • Multiple myeloma
  • Laryngeal cancer
  • von Hippel-Lindau syndrome
  • Esophageal cancer
CIITA class II major histocompatibility complex transactivator
  • Interferon gamma signaling
  • Combined immunodeficiencies (CIDs), including the following nine diseases: X-linked hyper IgM syndrome; CD40 deficiency hyper IgM syndrome; Purine nucleoside phosphorylase (PNP) deficiency; Omenn syndrome; MHC deficiency (HLA-class I); MHC deficiency (HLA-class II); Zap-70 deficiency; p56 Lck deficiency; CD8 deficiency
  • Bare lymphocyte syndrome (BLS) type2
COPS5 COP9 signalosome subunit 5
  • DNA Damage Recognition in GG-NER
  • Formation of TC-NER Pre-Incision Complex
  • Cargo recognition for clathrin-mediated endocytosis
  • Neddylation
  • GSK3B-mediated proteasomal degradation of PD-L1(CD274)
CR2 complement C3d receptor 2
  • Regulation of Complement cascade

Page 1 out of 5 pages